Scarica l'app Stockscreener
8.29
1.43%
-0.12
Dopo l'orario di chiusura:
8.29
Precedente Chiudi:
$8.41
Aprire:
$8.47
Volume 24 ore:
340.60K
Relative Volume:
0.76
Capitalizzazione di mercato:
$664.09M
Reddito:
-
Utile/perdita netta:
$-124.74M
Rapporto P/E:
-0.0157
EPS:
-527.5896
Flusso di cassa netto:
$-149.71M
1 W Prestazione:
+8.79%
1M Prestazione:
+6.15%
6M Prestazione:
-31.46%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$8.12
$8.625
Intervallo di 1 settimana:
$7.575
$8.625
Portata 52W:
$7.00
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
Nome
Bridgebio Oncology Therapeutics Inc
Settore
Industria
Telefono
857 702 0377
Indirizzo
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Compare BBOT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
8.29 | 673.70M | 0 | -124.74M | -149.71M | -527.59 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-11 | Iniziato | Stifel | Buy |
| 2026-01-09 | Iniziato | Raymond James | Outperform |
| 2025-12-05 | Iniziato | Morgan Stanley | Overweight |
| 2025-09-17 | Iniziato | Leerink Partners | Outperform |
| 2025-09-15 | Iniziato | H.C. Wainwright | Buy |
| 2025-08-15 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Bridgebio Oncology Therapeutics Inc Borsa (BBOT) Ultime notizie
BBOT (BBOT) COO Idan sees 343 shares withheld to cover RSU tax bill - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) officer reports tax-withheld RSU share disposition - Stock Titan
Tax withholding trims BridgeBio Oncology (BBOT) CEO Beltran’s share count - Stock Titan
Form 13D/A BridgeBio Oncology Therapeutics For: 6 July By Investing.com - Investing.com Canada
Cormorant funds restructure 22.3% BridgeBio Oncology (BBOT) stake, add lock-up - Stock Titan
Cormorant funds tied to BBOT (NASDAQ: BBOT) receive 4.53M shares in internal distribution - Stock Titan
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance
BridgeBio Oncology Therapeutics (BBOT) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Price to book forward of BridgeBio Oncology Therapeutics, Inc. – NASDAQ:BBOT - TradingView
Price to sales forward of BridgeBio Oncology Therapeutics, Inc. – BOATS:BBOT - TradingView
BridgeBio Oncology Therapeutics, Inc. Actuals & Estimates (NASDAQ:BBOT) - TradingView
BBOT Forecast — Price Target — Prediction for 2027 - TradingView
BridgeBio Oncology (BBOT) Faces Selling Pressure Amid Sector Rotation ConcernsDonchian Channel - dars.gov.et
BBOT Assumed by Oppenheimer -- Rating Remains Outperform - GuruFocus
BridgeBio Oncology (BBOT) registers 63.05M shares for selling holders - Stock Titan
Michelle Doig resigns from BridgeBio Oncology Therapeutics board effective June 16, 2026 - TradingView
BridgeBio Oncology (NASDAQ: BBOT) reports 2026 director elections and auditor ratification - Stock Titan
BridgeBio Oncology Therapeutics, Inc. Announces Resignation of Michelle Doig as Class I Director, Effective as of June 16, 2026 - marketscreener.com
Oppenheimer initiates BridgeBio Oncology stock rating at Outperform By Investing.com - Investing.com India
Oppenheimer initiates BridgeBio Oncology stock rating at Outperform - Investing.com
Oppenheimer Initiates BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Announces Target Price $22 - Moomoo
BridgeBio Oncology Therapeutics, Inc.(NasdaqGM:BBOT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026 - MarketBeat
BBOT Q1 2026 Earnings: Narrower-Than-Expected Loss Amidst Pre-Revenue StageBasic EPS Analysis - dars.gov.et
Director at BridgeBio Oncology (BBOT) granted options for 31,675 shares - Stock Titan
BridgeBio Oncology (BBOT) director receives 31,675-share stock option grant - Stock Titan
Director at BridgeBio Oncology (BBOT) receives 7,289 stock options - Stock Titan
BridgeBio Oncology (BBOT) director awarded 31,675 options at $7.73 strike - Stock Titan
Chen Bihua, director, granted 31,675 options at BridgeBio Oncology (BBOT) - Stock Titan
Director at BridgeBio Oncology Therapeutics (BBOT) awarded stock options - Stock Titan
BridgeBio Oncology (BBOT) director Neil Kumar granted 31,675 stock options at $7.73 - Stock Titan
BridgeBio Oncology Therapeutics Ord Shs (BBOT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BridgeBio Oncology Therapeutics Ord Shs (BBOT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BridgeBio Oncology Therapeutics Ord Shs (BBOT) Institutional Confidence - TradingKey
BBOT Stock Price, Quote & Chart - ChartMill
Number of shareholders of BridgeBio Oncology Therapeutics, Inc. – NASDAQ:BBOT - TradingView
BBOT Q1 2026 Earnings: Narrower Loss Surprises Modestly as Pre‑Clinical Pipeline ProgressesPretax Income Report - dars.gov.et
BridgeBio Oncology Therapeutics (BBOT) Climbs Nearly 4% as Support Holds FirmTotal Put Call - newsline.com
BridgeBio Oncology Therapeutics Inc. (BBOT) Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Advances - newsline.com
BBOT Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Progresses PipelineGross Profit Margin - newsline.com
Technical Analysis of BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) - TradingView
BBOT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock DeclineEarnings Call Transcript - newsline.com
BridgeBio Oncology Therapeutics (BBOT) Slips 5.35% as Biotech Headwinds PersistVolume Breadth - newsline.com
BridgeBio Oncology Therapeutics (BBOT) Stock Trends and Sentiment 2026 - MarketBeat
BridgeBio Oncology Therapeutics (BBOT) Earnings Date and Reports 2026 - MarketBeat
BridgeBio Oncology Therapeutics Inc. (BBOT) Edges Higher Amid Sector RotationHigh Reward Trades - The Legal Advocate
BBOTBridgeBio Oncology Therapeutics Inc Stock Price and Quote - Finviz
BridgeBio Oncology Therapeutics Inc. (BBOT) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Stem Stock SlideProfit Announcement - Newser
BBOT Dips Close to Lows With One Cancer Drug Update Steering Trade - Bez Kabli
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks - TipRanks
Bridgebio Oncology Therapeutics Inc Azioni (BBOT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):